NFKB1 and breast cancer: The combinatory treatment of EGCG and raloxifene (selective estrogen receptor modulator) reduced p65, a major subunit of NF-κB that was associated with reduced phosphorylation of the AKT, mTOR, EGFR, and S6K, and increased the phosphorylation of stress-activated protein kinases in MDA-MB-231 BC cells [168].